Investigating how PDL1 affects melanoma growth and progression
Official title: The role of tumor cell-of-origin-specific PDL1 on tumorigenesis and tumor progression
Funded at University of Texas Hlth Science Center · NIH-10913306 · Data updated 2026-11-12
This study is looking at how a protein called PDL1 affects the growth of melanoma, a type of skin cancer, using a special mouse model to help find new treatment options for people with this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 3, 2023 |
| Project end | August 2, 2027 |
| Funding year | 2024 |
| Award (this year) | $39,011 |
| NIH project number | 5F31CA281345-02 |
| Project ID | NIH-10913306 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with melanoma, particularly those in the early stages of the disease.
✕Less likely to help
Patients with advanced melanoma or those who do not express PDL1 may not benefit from this research.
What this research studies
This research explores the role of PDL1, a protein that may influence the development and progression of melanoma, a type of skin cancer. Using a specialized mouse model that mimics human melanoma, the study aims to understand how PDL1 signals from tumor cells contribute to tumor growth and response to treatment. The researchers will analyze changes in gene and protein expression as melanoma progresses, particularly focusing on the early stages of tumor development. This could provide insights into new therapeutic strategies targeting PDL1 in melanoma patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with melanoma by targeting PDL1 signaling.
How similar studies have gone: Previous research has shown promising results in targeting PDL1 in other cancers, suggesting potential for success in this area as well.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Ontiveros, Carlos Oscar — University of Texas Hlth Science Center
- Study coordinator: Ontiveros, Carlos Oscar
Related research
Other NIH-funded projects on the same topics.
-
LRP1 controls NSC movement and stroke recovery
This NIH grant studies how a brain receptor called LRP1 helps neural stem cells move to stroke injuries and support recovery in adults.
-
Rural microvascular factors driving brain aging and dementia
This project will study how blood vessel problems in rural communities contribute to brain aging and dementia, using mobile clinics to reach people who live far from major medical centers.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Gene editing therapies to prevent epileptic seizures
A new gene-editing approach aims to reduce seizures in people with epilepsy by directly modifying a brain gene tied to the condition.
-
Blocking the IL-4/13 pathway in allergic asthma and rhinoconjunctivitis to understand why treatments work differently
A high-quality clinical trial will test a targeted therapy in people with allergic asthma and allergic rhinitis to understand why symptoms and responses vary.
-
Hormonal Influences on Inflammation in Endometriosis
A study in adult women with endometriosis looks at how hormones and immune pathways interact to influence inflammation and symptoms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.